PDS Biotechnology Corporation PDSB Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.23 up $0.06, 5.13% at close Nov 6
Last close · Previous close $1.17
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.64Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.23up $0.06, 5.13%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.17Nov 5
- Volume2.95MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume8.23MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.20 to $1.79; now $1.23
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
PDSB beat the S&P 500 in 4 of 7 periods.
| Period | PDSB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PDSB: up 17.7% S&P 500: down 5.6% | PDSB beat the S&P 500 by 23.3 percentage points Beat |
| 3M | PDSB: up 64.6% S&P 500: down 4.1% | PDSB beat the S&P 500 by 68.7 percentage points Beat |
| YTD | PDSB: up 59.8% S&P 500: up 8.7% | PDSB beat the S&P 500 by 51.1 percentage points Beat |
| 1Y | PDSB: up 38.4% S&P 500: up 10.9% | PDSB beat the S&P 500 by 27.5 percentage points Beat |
| Long term | ||
| 3Y | PDSB: down 73.7% S&P 500: up 75.0% −35.9% vs +20.5% a year | PDSB trailed the S&P 500 by 148.7 percentage points Trailed |
| 5Y | PDSB: down 89.3% S&P 500: up 67.8% −36.0% vs +10.9% a year | PDSB trailed the S&P 500 by 157.1 percentage points Trailed |
| 10Y | PDSB: down 99.4% S&P 500: up 313.1% −40.1% vs +15.2% a year | PDSB trailed the S&P 500 by 412.5 percentage points Trailed |
$10,000 invested in PDSB 10 years ago (Nov 4, 2016) would be worth about $59 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
PDSB beat the S&P 500 in 4 of 7 periods.
| Period | PDSB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | PDSB: up 17.7% S&P 500: down 5.6% | PDSB beat the S&P 500 by 23.3 percentage points Beat |
| 3M | PDSB: up 64.6% S&P 500: down 4.3% | PDSB beat the S&P 500 by 68.9 percentage points Beat |
| YTD | PDSB: up 59.8% S&P 500: up 7.8% | PDSB beat the S&P 500 by 52.0 percentage points Beat |
| 1Y | PDSB: up 38.4% S&P 500: up 9.7% | PDSB beat the S&P 500 by 28.7 percentage points Beat |
| Long term | ||
| 3Y | PDSB: down 73.7% S&P 500: up 68.8% −35.9% vs +19.1% a year | PDSB trailed the S&P 500 by 142.5 percentage points Trailed |
| 5Y | PDSB: down 89.3% S&P 500: up 56.9% −36.0% vs +9.4% a year | PDSB trailed the S&P 500 by 146.2 percentage points Trailed |
| 10Y | PDSB: down 99.4% S&P 500: up 252.6% −40.1% vs +13.4% a year | PDSB trailed the S&P 500 by 352.0 percentage points Trailed |
$10,000 invested in PDSB 10 years ago (Nov 4, 2016) would be worth about $59 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$469.80
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Oct 1, 2015.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$33.67M
- Diluted EPS
- −$0.64
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$10.73M | −$0.29 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$7.95M | −$0.21 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$8.49M | −$0.21 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$9.43M | −$0.21 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$9.01M | −$0.19 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$7.56M | −$0.14 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$7.35M | −$0.13 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$9.75M | −$0.18 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$16.92M | −$0.66 |
| FY22 (Dec 31, 2022) | $0.00 | −$40.85M | −$1.43 |
| FY23 (Dec 31, 2023) | $0.00 | −$42.94M | −$1.39 |
| FY24 (Dec 31, 2024) | $0.00 | −$37.61M | −$1.03 |
| FY25 (Dec 31, 2025) | $0.00 | −$34.50M | −$0.74 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$16.78MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$16.78MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $10.37MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $5.60MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$4.36MAs of Jun 30, 2026
- Net cash$1.23MAs of Jun 30, 2026
- 0.57As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −708.2%Last 12 months
Over the last 12 months, PDS Biotechnology lost money: its net loss was 708.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −136.5%Last 12 months
Over the last 12 months, PDS Biotechnology’s net loss was 136.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About PDS Biotechnology Corporation
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate, EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage (cSDH). The company also develops other product candidates, which are in pre-clinical development stages, including EG-1964, to prevent recurrent bleeding after treatment for cSDH; and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
PDSB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
PDSB stock FAQ
What is PDSB stock’s price today?
PDS Biotechnology (PDSB) traded at $1.23 at the close on , up $0.06 (5.13%) from the previous close of $1.17. Over the past 52 weeks it has traded between $0.20 and $1.79.
If you invested $1,000 in PDSB 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in PDSB on would be worth about $6 at the close on , a total return of −99.4%. The same $1,000 would be worth $107 if invested five years ago and $1,384 if invested one year ago. Past performance doesn’t predict future returns.
What is PDSB’s P/E ratio?
PDSB’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.64).
What are PDSB’s earnings per share?
PDSB’s diluted earnings per share were −$0.64 over the four quarters to , compared with −$0.92 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.18 per share, against −$0.21 a year earlier (how EPS works).
Does PDSB pay a dividend?
PDS Biotechnology hasn’t paid a dividend in the last twelve months.
What is PDSB’s 52-week high and low?
Over the past 52 weeks PDSB has traded as low as $0.20 and as high as $1.79. At $1.23 at the close on , it is 31.3% below that high and 530.1% above the low.
What is PDSB’s all-time high?
PDSB’s highest closing price was $469.80 on , adjusted for stock splits. At $1.23 at the close on , it is 99.7% below that record.
Has PDSB stock ever split?
Yes, once: 1-for-20 on .
How has PDSB stock performed?
Including dividends and measured to the close on , PDSB has returned +59.8% so far this year and +38.4% over the past year, and −89.3% over five years (−36.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is PDS Biotechnology in?
PDS Biotechnology is in the Healthcare sector and the Biotechnology industry, and is headquartered in New Jersey, USA.
What exchange does PDSB trade on?
PDS Biotechnology trades on the Nasdaq under the ticker symbol PDSB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.